4 articles found
Browse Rainier Rehab's editorial coverage of Stimulant addiction. Our writers track federal and state policy, peer-reviewed research, treatment innovations, and frontline reporting from the addiction recovery field. Each article in this collection cites primary sources — government datasets (SAMHSA, NIH, CDC), Medicaid and Medicare bulletins, JAMA and Lancet studies, and on-the-record statements from clinicians, regulators, and people in recovery — so readers can verify claims and dig deeper.
We update this tag whenever new stimulant addiction reporting publishes. If you're a researcher, journalist, or family member trying to make sense of substance use disorder treatment, this is the working archive. For a directory of accredited treatment facilities, visit our facilities directory; to compare modalities, see our treatments overview and levels of care guide.
UC San Diego's new Polysubstance Addiction Research Center will study cocaine, oxycodone, alcohol and their combinations in one coordinated five-year program.
A randomized quadruple-blind trial found psilocybin-assisted therapy achieved 30% complete abstinence at 180 days vs 0% with placebo, with 72% reduced relapse risk.
Landmark UC San Diego study reveals first decline in all four waves of overdose epidemic, driven by falling fentanyl deaths, while stimulant-related fatalities continue rising.
Phase 3 study of 339 adults finds cheap, widely available medication cuts meth use by seven days per month, offering first pharmacological treatment option for stimulant use disorder.